Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 4/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.36 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758174 | 0.95 | NPY5R (0.41) | TFPINPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL25759233 | 0.95 | NPY5R (0.39) | TFPINR3C1NPY5RNPY4RNPY1R | |
| SCHEMBL25758366 | 0.92 | NPY4R (0.37) | TFPINPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL25759551 | 0.76 | NPY4R (0.45) | NPY5RNPY4RNPY1RNPY2RKISS1R | |
| SCHEMBL24155349 | 0.76 | NPY4R (0.45) | NPY5RNPY4RNPY1RNPY2RKISS1R | |
| SCHEMBL25758506 | 0.75 | NPY4R (0.44) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL29659738 | 0.74 | NPY4R (0.44) | NPY5RNPY4RNPY1RNPY2RPTH1R | |
| SCHEMBL32690565 | 0.73 | NPY4R (0.51) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL30811145 | 0.73 | NPY4R (0.47) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL29659796 | 0.73 | TFPI (0.53) | TFPINR3C1NPY5RNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VITEK, MICHAEL PETER | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VIP, NPPA, IAPP | TFPI 484/4885NR3C1 2816/4885NPY5R 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.